

FILE COPY

RECEIVED

NOV 09 2000

#18

FORM PTO-1449

SECOND SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1488.1310002/EKS/EJHAPPLICATION
09/042,583APPLICANT
NI et al.FILING DATE
March 17, 1998GROUP
1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	TRANSLATION
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN1	WO 99/02653	01/21/1999	WIPO PCT			Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

<input checked="" type="checkbox"/>	AR	1	Chaudhary, P.M. et al., "Death Receptor 5, a New Member of the TNFR Family, and DR4 Induce FADD-Dependent Apoptosis and Activate the NF- κ B Pathway," <i>Immunity</i> 7:821-830 (December 1997).
<input checked="" type="checkbox"/>	AS	1	Marsters, S.A. et al., "A novel receptor for APO2L/TRAIL contains a truncated death domain," <i>Curr. Biol.</i> 7:1003-1006 (December 1997).
<input checked="" type="checkbox"/>	AT	1	Rieger, J. et al., "APO2 ligand: a novel lethal weapon against malignant glioma?" <i>FEBS Lett.</i> 427:124-128 (May 1998).

EXAMINER


Claus M. K.

DATE CONSIDERED

4/18/01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

SECOND SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1488.1310002/EKS/EJHAPPLICATION NO.
09/042,583APPLICANT
NI et al.FILING DATE
March 17, 1998GROUP
1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

<input checked="" type="checkbox"/>	AR	2 -	Schneider, P. et al., "TRAIL Receptors 1 (DR4) and 2 (DR5) Signal FADD-Dependent Apoptosis and Activate NF- κ B," <i>Immunity</i> 7:831-836 (December 1997).
<input checked="" type="checkbox"/>	AS	2 -	Sheikh, S.M. et al., "p53-dependent and -independent Regulation of the Death Receptor KILLER/DR5 Gene Expression in Response to Genotoxic Stress and Tumor Necrosis Factor α ," <i>Cancer Res.</i> 58:1593-1598 (April 1998).
<input checked="" type="checkbox"/>	AT	2 -	Zamai, et al., "Natural killer (NK) Cell-mediated Cytotoxicity: Differential Use of TRAIL and Fas Ligand by Immature and Mature Primary Human NK Cells," <i>J. Exp. Med.</i> 188:2375-2380 (December 1998).

EXAMINER

DATE CONSIDERED

4/18/01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1488.1310002APPLICANT
NI et al.FILING DATE March 17, 1998
(CPA filed July 24, 2000)APPLICATION NO.
042,583GROUP
1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
<input checked="" type="checkbox"/> CK	AA1	6,072,047	06/06/2000	Rauch et al.	536	23.5	06/26/1997
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR		
	AS		
	AT		

EXAMINER

Clara M. Key

DATE CONSIDERED

4/18/01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.